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Hemophilia A, one of the most common genetic bleeding disor-
ders, is caused by various mutations in the blood coagulation fac-
tor VIII (F8) gene. Among the genotypes that result in hemophilia A,
two different types of chromosomal inversions that involve a
portion of the F8 gene are most frequent, accounting for almost
half of all severe hemophilia A cases. In this study, we used a tran-
scription activator-like effector nuclease (TALEN) pair to invert
a 140-kbp chromosomal segment that spans the portion of the
F8 gene in human induced pluripotent stem cells (iPSCs) to create
a hemophilia A model cell line. In addition, we reverted the
inverted segment back to its normal orientation in the hemophilia
model iPSCs using the same TALEN pair. Importantly, we detected
the F8 mRNA in cells derived from the reverted iPSCs lines, but not
in those derived from the clones with the inverted segment. Thus,
we showed that TALENs can be used both for creating disease
models associated with chromosomal rearrangements in iPSCs
and for correcting genetic defects caused by chromosomal inver-
sions. This strategy provides an iPSC-based novel therapeutic op-
tion for the treatment of hemophilia A and other genetic diseases
caused by chromosomal inversions.
genome editing | CRISPR | Cas9 | ZFN
Hemophilia A is one of the most common genetic bleedingdisorders, with an incidence of 1 in 5,000 males worldwide
(1). This disorder is caused by various genetic mutations, which
include large deletions, insertions, inversions, and point muta-
tions, in the X-linked coagulation factor VIII (F8) gene (Hae-
mophilia A Mutation, Structure, Test and Resource Site; http://
hadb.org.uk); a total of 1,492 different mutations are known to
cause hemophilia A. Clinical symptoms vary widely according to
the genotypes (2). Hemophilia A can be characterized as severe
(<1% activity), moderate (1–5% activity), or mild (5–30% ac-
tivity), depending on the relative amount of F8 activity in the
patient’s plasma (1). Approximately 50% of severe hemophilia
A cases are caused by two different types of chromosomal inver-
sions that involve a part of the F8 gene (3–5).
Currently, there is no cure for hemophilia A. Recombinant F8
protein has been used for the treatment of this condition, but is
limited by the formation of F8-inactivating antibodies, high cost,
and the requirement for frequent injections. Gene therapy is
a promising option for the cure of hemophilia. Remarkably,
Nathwani et al. used an adeno-associated virus vector (AAV) to
deliver the F9 cDNA, which encodes blood coagulation factor
IX, to six patients with hemophilia B, a less common form of
X-linked bleeding disorder (6). Unfortunately, however, this vec-
tor cannot be used to deliver the full-length F8 cDNA to patients
with hemophilia A because AAV cannot accommodate the large
size of the F8 cDNA (∼8 kbp). In contrast, the F9 cDNA is much
smaller (∼1.4 kbp). Besides, gene therapy is ideally used to
correct genetic defects rather than to deliver a functional gene
that is not under endogenous regulatory control.
Patient-derived induced pluripotent stem cells (iPSCs) provide
another promising option for the cure of hemophilia. Patient-
derived iPSCs per se, however, cannot be used in cell therapy
because they contain the original genetic defect. Importantly, the
defective gene can be corrected in iPSCs by using programmable
nucleases, which include zinc finger nucleases (ZFNs) (7–10),
transcription activator-like effector nucleases (TALENs) (11–13),
and clusters of regularly interspaced palindromic repeats
(CRISPR)/Cas-derived RNA-guided endonucleases (RGENs; or
engineered nucleases) (14–21). These programmable nucleases
cleave chromosomal DNA in a targeted manner, producing
DNA double-strand breaks (DSBs), whose repair via endoge-
nous mechanisms, known as homologous recombination (HR) or
nonhomologous end-joining (NHEJ), gives rise to targeted mu-
tagenesis and chromosomal rearrangements such as deletions
(22, 23), duplications, and inversions (24). Gene-corrected iPSCs
are then differentiated into appropriate somatic cells before
delivery to patients to ensure the expression of the corrected gene
and to prevent teratoma formation in patients.
In this study, we show that TALENs can be used to invert the
140-kbp chromosomal segment in human iPSCs to create he-
mophilia A model cell lines that recapitulate one of the most
frequent genotypes of hemophilia A and to flip-flop the inverted
region back to the wild-type state. Importantly, the F8 mRNA
is expressed in cells differentiated from reverted—i.e., genome-
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corrected—iPSCs but not in cells differentiated from the
hemophilia model iPSCs. To the best of our knowledge, this
report is the first demonstration that engineered nucleases can
be used to rearrange large genomic segments in iPSCs and to
isolate clones harboring such genomic rearrangements, providing
a proof-of-principle for correcting genetic defects caused by
genome rearrangements in iPSCs.
Results
Generation and Characterization of Human iPSCs. We derived wild-
type iPSCs from human dermal fibroblasts (HDFs) using epi-
somal vectors that encode the four Yamanaka factors, which we
introduced into cells by electroporation. Embryonic stem cell
(ESC)-like colonies appeared 10 d after replating of transfected
cells onto a feeder cell layer. We selected a total of eight colonies
(termed Epi1–Epi8) exhibiting alkaline phosphatase activities
(Fig. 1 A and B). To confirm the absence of episomal vectors in
these clones after seven or eight passages, we used PCR with spe-
cific primers for the EBNA-1 sequence, which is encoded in the
vectors. Only one clone (Epi1) contained the EBNA-1 sequence;
this clone was excluded from further analyses (Fig. 1C). Next, we
checked the karyotypes of two iPSC lines (Epi3 and Epi8). As
shown in Fig. S1A, they had a normal karyotype. We also con-
firmed that these iPSC lines were derived from parental HDFs
using DNA fingerprinting analysis (Table S1). After these initial
characterizations, we chose the Epi3 line for further experi-
ments. This iPSC line expressed the typical ESC marker proteins
such as OCT4, NANOG, SSEA-4, and TRA-1-60 (Fig. 1D and
Fig. S1B). RT-PCR and quantitative PCR (qPCR) analyses showed
that pluripotent marker genes were expressed at higher levels in
this iPSC line than in the human ESC line H9 (Fig. 1 E and F).
Next, we determined the differentiation potential of the Epi3
iPSC line. Embryonic bodies were derived and attached to gel-
atin-coated culture plates for spontaneous differentiation into
three germ layers in vitro. As expected, marker proteins for ec-
toderm (Nestin and Pax6), mesoderm [α-smooth muscle actin
(α-SMA) and Brachyury], and endoderm [α-fetoprotein (AFP)
and hepatocyte nuclear factor 3-β (HNF3β)] lineages were
expressed in the differentiated cells (Fig. 1G and Fig. S1C).
These data indicate that the Epi3 line derived from adult HDFs
is pluripotent.
Targeted Inversion of the F8 Locus in iPSCs Using a TALEN Pair.
Structural variations (SVs) such as inversions are associated
with genetic diseases including hemophilia A (25). Almost half of
all severe hemophilia A cases are caused by two different types
of inversions that disrupt the integrity of the X-linked F8 gene.
These inversions result from nonallelic HR (NAHR) that involves
sequences present in intron 1 (1–4% of severe hemophilia A
cases) or intron 22 (up to 50% of severe hemophilia A cases) and
their corresponding homologous sequences located far upstream
of the F8 gene (referred to as the intron 1 or 22 inversion, re-
spectively) (3, 4). In this study, we focused on the intron 1 in-
version and constructed 11 pairs of TALENs that target the
intron 1 homolog (Fig. 2A). The genome-editing activities of
these TALENs were tested in HEK 293T cells by using T7 en-
donuclease I (T7E1) assays (10) (Fig. 2B). We chose the most
active TALEN pair (termed TALEN 01) that induced mutations
with a frequency of 33% at the target site. Importantly, this
TALEN induced the 140-kb inversion that involves the intron 1
homolog in HEK 293T cells at a frequency of 1.9% (Fig. S2).
Next, we tested whether this TALEN had off-target effects at
highly homologous sites. No off-target mutations were detected
at these sites by using T7E1 assays (Fig. S3 and Table S2).
We then used the same TALEN pair to induce the 140-kb
inversion in iPSCs and to create a hemophilia model cell line.
Wild-type iPSCs were electroporated with the TALEN plasmids
and cultured for 10 d to form colonies. Genomic DNA samples
isolated from each colony were subjected to PCR by using spe-
cific primer sets that detect the inversion event. Six colonies of
432 (1.4%, comparable to that in HEK 293 cells) showed positive
PCR bands for the two inversion breakpoint junctions. Four
colonies were then further cultured to derive single cell clones.
These clones produced PCR bands that are diagnostic of the
140-kb inversion but, importantly, did not produce PCR bands
that correspond to the wild-type genotype (Fig. 3A). Next, we
cloned these PCR products and determined their DNA sequences
to confirm the inversion genotype. No indels were found at the
TALEN target sites (Fig. 3B). This result suggests that a single
DSB that was induced by the TALEN in either the intron 1 ho-
molog 1 or homolog 2 triggered DNA inversion via error-free
NAHR. However, we cannot rule out the possibility that the
TALEN produced two concurrent DSBs—one in the intron ho-
molog 1 and the other in homolog 2—and that these DSBs were
joined seamlessly by NHEJ without leaving secondary mutations.
Targeted Reversion of the Inverted Segment in the iPSC System. In
our previous report, we induced the targeted chromosomal in-
version that involves the intron 1 homolog in the HEK 293 cell
line using a ZFN pair and isolated heterozygous clones that
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Fig. 1. Generation of iPSC clones from HDFs using episomal reprogramming
vectors. (A) Morphology of the expanded human iPSCs (clone Epi3). (Scale
bar, 200 μm.) (B) Alkaline phosphatase staining of iPSCs (clone Epi3). (Scale
bar, 500 μm.) (C) Detection of an episomal vector sequence (EBNA-1) that
remained in established iPSC lines (Epi1–Epi8). The GAPDH gene was used as
a quality control for isolated total DNA. Total DNA isolated from the cells
before (naïve) and after (day 6) electroporation was used as negative and
positive controls for episomal vector DNA. A retrovirus-derived wild-type
iPSC line (iPSC1) was also analyzed as a negative control. (D) The expression
of OCT4 and SSEA-4, which are human ESC-specific markers, was detected by
immunocytochemistry. DAPI signals indicate the total cell presence in the
image. (Scale bars, 100 μm.) (E) RT-PCR analysis to determine the transcrip-
tional levels of OCT4, SOX2, LIN28, NANOG, and GAPDH using gene-specific
primers (listed in Table S3). mRNA levels were measured in HDFs, human ES
line (H9), a wild-type iPSC line (WT-iPSCEpi3), and inversion clones (Inv 1 and
Inv 2) derived from the WT-iPSCEpi3 line (1, HDFs; 2, H9; 3, WT-iPSC; 4, Inv 1;
5, Inv 2). (F) Quantification of OCT4, SOX2, and LIN28 mRNAs in the in-
dicated cell lines as determined by qPCR and normalized to GAPDH ex-
pression. (G) Expression of marker proteins representing ectoderm (Nestin),
mesoderm (α-smooth muscle actin; α-SMA), and endoderm (α-fetoprotein;
AFP). (Scale bars, 50 μm.)
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harbor the inversion (24). However, HEK 293 cells do not ex-
press the F8 gene and cannot be used in cell therapy. Further-
more, HEK 293 cells carry three copies of the X chromosome.
These limitations hampered our efforts to revert the inverted re-
gion back to the normal orientation to restore expression of the F8
gene, a demonstration required for therapeutic applications.
In this study, we investigated whether the inverted 140-kbp
segment in the hemophilia model iPSC line could be corrected
by reversion using the same TALEN pair. (Note that the
TALEN site remains intact in the model cell line.) The TALEN
plasmids were transfected into two iPSC clones containing the
inversion (referred to here as “inversion clones”), and then ge-
nomic DNA samples isolated from several colonies were sub-
jected to PCR to identify reverted cells. We obtained two
reverted clones from each of the iPSC clones after screening
a total of 300 colonies. Thus, the reversion frequency was 1.3%
(4 of 300), on par with the inversion frequency. PCR analysis
revealed that the genotype of these reverted clones was consis-
tent with a reversion to wild type: No inversion-specific PCR
bands were detected in the samples from these clones (Fig. 4A).
We then cloned and sequenced these PCR products containing
homolog 1 or 2. Two clones had no additional mutations, but the
other two clones had 2-bp deletions at the two TALEN sites in
both homologs 1 and 2 (Fig. 4B). These results show that the
inversion genotype found in severe hemophilia A can be cor-
rected by using the same TALEN pair that was used to generate
the disease model.
In addition, we investigated whether both the inversion clones
and reverted clones remained pluripotent by checking their ex-
pression of human ES marker genes and their ability to undergo
differentiation into the three primary germ layers. These clones
expressed stem cell marker genes at levels comparable with those
in wild-type iPSCs (Fig. 1F and Fig. S4) and differentiated into
three germ layers in vitro (Fig. S5). These results show that
TALEN-mediated genome engineering does not negatively af-
fect iPSC pluripotency.
F8 Gene Expression in Cells Differentiated from Reverted iPSCs. The
F8 gene is expressed in hepatocytes and endothelial cells (26–
29), which are derived from endoderm and mesoderm, re-
spectively. First, we examined whether the F8 gene could be
expressed in endodermal cells derived from the wild-type and
reverted iPSC clones. We differentiated iPSCs into endoderm
and performed an RT-PCR analysis to detect the F8 mRNA. As
expected, the F8mRNA was detected in cells differentiated from
the wild-type and reverted iPSC clones (Fig. 5A). By contrast, no
F8 mRNA was detected in cells derived from the iPSCs with the
inversion, although these cells could differentiate into endoderm
as efficiently as wild-type and reverted iPSCs. Next, we examined
the expression of the F8 protein in endothelial cells, which are
the main source of production of the F8 protein (28). We dif-
ferentiated iPSCs into endothelial cells and performed immu-
nostaining to detect the F8 protein. As expected, the cells
differentiated from wild-type and reverted iPSC clones expressed
the F8 protein (Fig. 5B). However, the F8 protein was not
detected in the cells differentiated from the inversion clone, al-
though this iPSC clone differentiated successfully into endothe-
lial cells as shown by the expression of von Willebrand factor,
a mature endothelial cell marker protein. These results prove
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Fig. 2. TALEN-mediated inversion of the F8 gene in HEK 293T cells. (A)
Proposed mechanism of a chromosomal inversion found in patients with
severe hemophilia A. Inversions of 140-kbp chromosomal segments span-
ning the F8 gene are associated with two homologous regions oriented in
opposite directions: homolog 1 located in intron1 of the F8 gene and
homolog 2 located in the 140-kbp upstream region. Colored triangles
show TALEN target sites, and arrows indicate the primers designed to
detect 140-kbp inversions. (B) T7E1 assay results of the 11 TALEN pairs we
designed. The predicted positions of DNA bands cleaved by T7E1 are in-
dicated by asterisks.
A
B
Fig. 3. TALEN-mediated inversion of the F8 locus in iPSCs. (A) PCR analysis
of genomic DNA from four inversion clones. Genomic DNA samples isolated
from hemophilia A patient cells (Pa) or wild-type iPSCs (WT) served as pos-
itive controls for the inversion or normal genotypes, respectively. (B) DNA
sequences of breakpoint junctions in inversion clones. TALEN binding sites
are shown in red (homolog 1) or blue (homolog 2).
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that the integrity of the F8 gene is restored in reverted iPSCs,
which supports expression of the F8 gene in endodermal cells
and mesoderm-derived endothelial cells.
Discussion
Over the past decade, next-generation sequencing technologies
have revealed numerous SVs or copy number variations in in-
dividual human genomes (30, 31). SVs include deletions, duplica-
tions, and inversions that involve chromosomal segments whose
sizes range from hundreds to millions of base pairs. These varia-
tions are associated with diverse phenotypes such as disease
susceptibility. To study the biological consequences of individual
SVs of interest in cultured cells such as iPSCs or model organ-
isms, one must be able to construct genome-modified clones that
harbor such variations and compare them with isogenic wild-
type controls.
Three different molecular mechanisms have been postulated
to explain the etiology of these variations: NAHR, NHEJ, and
DNA replication errors (32). Among these, NAHR and NHEJ
are triggered by DNA DSBs, which are produced randomly in
the genome by various environmental, chemical, and biological
stresses. DSBs can also be produced by programmable nucleases
in a targeted manner. Indeed, we and others have shown that
programmable nucleases can be used to create SVs in human
cancer cell lines and animals (22, 24, 33, 34). In this study, we
extended this approach further by inverting the 140-kbp chro-
mosomal segment that includes the upstream sequence in the F8
gene in human iPSCs to create model cell lines that recapitulate
one of the most frequent genotypes of hemophilia A and, then,
reverting the segment back to the normal state to demonstrate
a proof-of-principle for gene/cell therapy.
Three different programmable nucleases are now available to
create SVs: ZFNs, TALENs, and Cas9 RGENs (35). ZFNs and
TALENs share the same nuclease domain—which is derived
from FokI, a type IIS restriction endonuclease—but differ in
their DNA-binding domains: ZFNs contain zinc finger proteins,
and TALENs contain TAL effector arrays derived from Xan-
thomonas, a plant pathogen. Unlike these FokI-based nucleases,
RGENs consist of Cas9 protein and guide RNA, and their DNA
cleavage specificities are governed by Watson–Crick base pairing
of guide RNA with target DNA sequences. We have developed
all of these nucleases for the last several years (10, 12, 17, 36–39)
and found that functional ZFNs were the most difficult to make
and were often associated with cytotoxicity (10). Still, we were
able to use a ZFN pair to invert the 140-kbp segment that
contains the promoter and upstream sequence in the F8 gene in
HEK 293 cells (24). However, the efficiency of this inversion,
even in the highly transfectable HEK 293 cell line, was very low
(0.1%). We isolated 3 inversion clones among 3,000 single cells
using this ZFN. To improve the frequency of inversion, we tested
11 TALENs in this study that are designed to target the F8 intron
homolog 1 and chose the best-performing TALEN. This TALEN
inverted the 140-kbp chromosomal segment at a frequency of
1.9%. This high efficiency allowed us to isolate iPSC clones with
the inversion genotype and those with the restored genotype.
The use of surrogate reporters (40–42) may facilitate the iso-
lation of clones that harbor chromosomal inversions further.
Importantly, we showed that F8 was expressed in cells derived
from reverted iPSCs, but not in cells derived from inverted iPSCs.
A
B
Fig. 4. Reversions of the F8 gene inversion. (A) PCR analysis is of genomic
DNA from three reverted clones. Genomic DNAs isolated from hemophilia A
patient cells (Pa) or wild-type iPSCs (WT) served as positive controls for in-
version or normal genotypes, respectively. (B) DNA sequences of breakpoint
junctions in reverted clones. TALEN binding sites are shown in red (junction 1)
or blue (junction 2). Dashes indicate deleted bases. The chromatograms show
the sequences (of homolog 1 and 2, respectively) between two TALEN bind-
ing sites in reverted clones (clones 1 and 3).
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Fig. 5. Characterization of inverted and reverted clones. (A) F8 gene ex-
pression in cells derived from inverted and reverted clones. RT-PCR was used
to detect expression of F8 and endoderm marker genes (FOXA2 and Sox17)
in cells derived from wild-type iPSCs (WT), inversion clones (Inv 1 and 2), and
reverted clones (Rev 1, 2, and 3). GAPDH served as a loading control. (B)
Expression of the F8 protein in endothelial cells differentiated from inverted
and reverted clones. The differentiated cells were fixed and stained with the
indicated antibodies. DAPI signals indicate the total cell presence in the
image. FVIII, F8 protein; vWF, von Willebrand factor (a mature endothelial
marker protein). (Scale bars, 100 μm.)
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We do not know whether the chromosomal flip-flop was me-
diated by NAHR or NHEJ. Because we used a TALEN pair
to target the homolog sequence, it is equally possible that two
concurrent DSBs were produced, which were then repaired by
NHEJ, or that a single DSB triggered DNA repair via NAHR.
DSB repair via NHEJ often gives rise to indels at the breakpoint
junction. We did find two-base deletions at the TALEN target
site in some reverted clones. These deletions can be produced
during inversion or after inversion. Thus, these deletions do not
rule out the possibility that chromosomal inversions were me-
diated by NAHR. Importantly, these small deletions provide
strong evidence that reverted clones were generated by TALEN-
mediated chromosomal flip-flop from the inversion clone rather
than derived from rare contaminating wild-type cells. To the best
of our knowledge, this is the first report that chromosomal seg-
ments can be inverted and then reverted in cells or organisms.
In summary, we demonstrated that TALENs can be used to
induce targeted inversions in human iPSCs that recapitulate one
of the most frequent genotypes responsible for severe hemo-
philia A. Furthermore, we restored the inverted 140-kbp DNA
segment back to the normal orientation using the same TALEN,
which resulted in expression of the F8 gene in cells differentiated
from genome-corrected iPSCs. This approach can be used for
autologous stem cell therapy to treat hemophilia A patients
harboring chromosomal inversions. Genomic inversions are also
associated with cancer (43) and genetic diseases such as Hunter
syndrome (44). Programmable nucleases can be used to correct
these genetic defects in patient-derived cells. In addition, we
expect that engineered nucleases will be widely used to create
SVs in iPSCs to study the resulting phenotypes.
Materials and Methods
Plasmids Encoding TALENs. TALEN plasmids in this study were synthesized by
using TAL effector array plasmids constructed for one-step Golden-Gate
assembly as described (12). Each TALEN plasmid encodes the N-terminal 135
amino acids of AvrBs3, an array of RVD modules, one of the four RVD half-
repeats, and the Sharkey FokI domain (45). TALEN sites were designed to
target the intron 1 homolog of the F8 gene; potential off-target sites were
identified as described (12).
Isolation of Genomic DNA from Hemophilia A Patient. Seoul National Univer-
sity Institutional Review Board approval was obtained for the analysis of
blood cells of a hemophilia A patient. The blood sample was provided by
Korea Hemophilia Foundation Clinic, and genomic DNA was isolated as
described (24).
Measuring the Frequencies of Targeted Inversions. The frequencies of targeted
inversions were estimated by digital PCR analysis as described (23). The ge-
nomic DNA samples isolated from cell transfected with TALEN plasmids were
serially diluted, and the diluted samples were subjected to nested PCR by
using appropriate primers (Table S3). The fraction of positive bands at each
dilution point was counted, and the results were analyzed by using the
Extreme Limiting Dilution Analysis program (46).
Cell Cultures. HEK 293T/17 (ATCC; CRL-11268) and adult HDFs (Invitrogen;
C-004-5C) were cultured in DMEM supplemented with FBS (10% vol/vol) and
antibiotics (1%). Human ESC (hESC) lines (H9) obtained from WiCell, retro-
virus-derived wild-type iPSCs (iPSC1), and iPSCs generated in this study were
maintained in hESC medium composed of DMEM/F12 medium supple-
mented with 20% (vol/vol) knockout serum replacement (Invitrogen), 4.5 g/L
L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, and
4 ng/mL basic FGF (PeproTech) as described (47, 48).
Validation of TALENs Targeting the F8 Locus in HEK 293T Cells. To validate the
genome-editing activities of the TALENs designed for this study, each TALEN
pair was transfected into HEK 293T cells, and their activities were measured
by using the T7E1 assay (10). To measure the frequency of targeted inversions
induced by TALENs targeting the F8 locus, HEK 293T/17 cells were seeded at
80% confluency before transfection and transfected by using Lipofectamine
2000 (Invitrogen) with TALEN-encoding plasmids. Genomic DNA samples
were isolated and subjected to PCR analysis to confirm chromosomal in-
version as described (23).
Generation of iPSCs and in Vitro Differentiation into Three Germ Layers. Epi-
somal vectors encoding defined reprogramming factors were used as
reported (49). In brief, HDFs grown in DMEM supplemented with 10% FBS
were electroporated by using a microporator system (Neon; Invitrogen) with
episomal vector mixtures (total 3 μg) according to the manufacturer’s in-
structions. After being pulsed three times with a voltage of 1,650 for 10 ms,
the cells were grown further in DMEM (containing 10% FBS). Seven days
after transfection, cells were transferred onto a feeder layer. iPSC colonies
that looked similar to hESCs were picked up mechanically and further cul-
tured for characterization.
In vitro differentiation of the iPSCs into three germ layers was induced as
described (50, 51). Embryoid bodies (EBs), formed by partially dissociating
iPSCs using collagenase type IV (Invitrogen), were transferred to ultralow
attachment plates (Corning) and cultured in DMEM/F12 (1:1) medium sup-
plemented with 20% knockout serum (Invitrogen), 4.5 g/L L-glutamine, 1%
nonessential amino acids, 0.1 mM 2-mercaptoethanol, and 5% FBS. After
a week of cultivation under these conditions, EBs were attached onto
Matrigel-coated culture dishes and further cultured for 10 d. Spontaneous
differentiation of EBs into cells representing the three germ layer lineages
was detected by immunostaining with appropriate antibodies.
Differentiation of iPSCs. To induce differentiation of iPSCs into the endoderm
lineage, we used a described method (52). In brief, iPSC colonies were cul-
tured in mTeSR-1 hESC growth medium (StemCell Technology) for feeder-
free culture (53). Undifferentiated iPSCs were incubated to obtain definitive
endoderm cells in RPMI/B27 (RPMI-1640 from Sigma; B27 supplement from
Invitrogen) medium supplemented with 100 ng/mL Activin A (PeproTech)
and 5 μM phosphatidylinositol 3–kinase inhibitor (LY-294002; Sigma) for 5 d.
Cells that had differentiated into endoderm were harvested for isolation of
total RNAs, which were used as template for cDNA synthesis.
To induce differentiation of iPSCs into the endothelial cells, we used a
described method (54) with slight modifications. In brief, EBs were cultured
in hESC medium supplemented with 20 ng/mL bone morphogenic protein 4
(R&D Systems) and 10 ng/mL Activin A (PeproTech). On day 3 of EB forma-
tion, the EBs were attached onto Matrigel-coated dishes and induced to
differentiate into endothelial cells for up to 10 d in medium supplemented
with 100 ng/mL VEGF (PeproTech) and 50 ng/mL basic FGF (R&D Systems).
TALEN Transfections for Inducing Inversion and Reversion in iPSCs. Cultured
iPSCswere harvested by treatingwith collagenase type IV. After washingwith
PBS, the cells were further treatedwith Accutase (Invitrogen) to create single-
cell suspensions as described (55). These single cells were mixed with 10 μg of
TALEN-encoding plasmids (5 μg of each plasmid) and pulsed with a voltage
of 850 for 30 ms. Cells were then seeded onto feeder cells and allowed to
grow for 10 d. To detect genomic inversion or reversion events, cells from
individual colonies were lysed in 20 μL of lysis buffer [1× Ex-taq buffer (pH
8.0) containing proteinase K] at 56 °C for 3 h. After inactivation of proteinase
K, 2 μL of genomic DNA solution was subjected to PCR by using Ex-taq DNA
polymerase (Takara) and specific primers. PCR products were analyzed by
agarose gel electrophoresis. Specific primer sequences are shown in Table S3.
Isolation of Clonal Populations of Cells, PCR Analysis, and DNA Sequencing of
Breakpoints. To isolate clonal populations of inverted (or reverted) cells, each
colony that had been identified by PCR as containing the desired genomic
event was dissociated into single cells by using collagenase and Accutase as
described above and replated. After three rounds of passaging, several clones
(six clones for inversion, four clones for reversion) were chosen for sequencing
and further experiments. For sequence determination, amplified PCR prod-
ucts were electrophoresed, eluted from the agarose gel by using a Gel Ex-
traction kit (SolGent), and cloned into the pGEM-T vector (Promega). Cloned
PCR products were sequenced by using T7 primers.
RNA Isolation, RT-PCR, and qPCR. Total RNAs were purified from cells by using
TRIzol reagent (Invitrogen) according to the manufacturer’s instructions.
cDNAs were synthesized from total RNAs (1 μg) by using the DiaStar cDNA
synthesis kit (SolGent). To confirm the expression of Factor VIII, FOXA2,
Sox17, and GAPDH, PCR was performed with Ex-Taq (Takara) by using the
synthesized cDNAs as template. For qPCR, SYBR Premix Ex-Taq (Takara) was
used according to the manufacturer’s instructions. Specific primer sequences
used for RT-PCR or qPCR are shown in Table S3.
Alkaline Phosphatase Staining and Immunostaining. Alkaline phosphatase
activity was measured with the leukocyte alkaline phosphatase staining
kit (Sigma) according to the manufacturer’s instructions. For the immu-
nostaining of pluripotent stem cell markers, cells were fixed in 4%
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paraformaldehyde solution and permeabilized with 0.2% Triton X-100. Af-
ter washing with PBS, the cells were incubated with a PBS solution con-
taining 5% normal goat serum and 2% BSA. The cells were then incubated
with primary antibodies for 2 h at room temperature, washed with PBS, and
incubated with fluorescence-conjugated secondary antibodies (Alexa Fluor
488 or 594; Invitrogen) for 1 h at room temperature. The cells were mounted
with an antifade mounting medium containing DAPI (Vector Laboratories)
for nuclei visualization. The images were captured and analyzed by using an
Olympus IX71 microscope or FSX system.
DNA Fingerprinting and Karyotype Analysis. To confirm the dermal fibroblast
origin of iPSC lines, PCR-based short tandem repeat (STR) analysis was carried
out at the Gene-Analysis Institute of Human Pass Inc. In brief, STR loci were
amplified from genomic DNA samples isolated from iPSC lines and their
parental cells by using the AmpFISTR PCR system (Applied Biosystems). The
amplified products were analyzed by using an ABI PRISM 3130XL genetic
analyzer and Genemapper (Version 3.2; Applied Biosystems). For karyotype
analysis, chromosomes were stained with Giemsa for G-banding analysis and
analyzed by the Chromosome Image Processing System at GenDix.
Statistical Analysis. Data are presented as means ± SEs. Student t test was
used for statistical analysis. P < 0.05 was considered statistically significant.
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